Literature DB >> 23791076

Vialinin A is a ubiquitin-specific peptidase inhibitor.

Kiyoshi Okada1, Yue Qi Ye, Kayoko Taniguchi, Ayaka Yoshida, Tomonori Akiyama, Yasukiyo Yoshioka, Jun-ichi Onose, Hiroyuki Koshino, Shunya Takahashi, Arata Yajima, Naoki Abe, Shunsuke Yajima.   

Abstract

Vialinin A, a small compound isolated from the Chinese mushroom Thelephora vialis, exhibits more effective anti-inflammatory activity than the widely used immunosuppressive drug tacrolimus (FK506). Here, we show that ubiquitin-specific peptidase 5/isopeptidase T (USP5/IsoT) is a target molecule of vialinin A, identified by using a beads-probe method. Vialinin A inhibited the peptidase activity of USP5/IsoT and also inhibited the enzymatic activities of USP4 among deubiquitinating enzymes tested. Although USPs are a member of thiol protease family, vialinin A exhibited no inhibitions for other thiol proteases, such as calpain and cathepsin.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23791076     DOI: 10.1016/j.bmcl.2013.05.093

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  14 in total

Review 1.  Deubiquitylating enzymes: potential target in autoimmune diseases.

Authors:  Niraj Parihar; Lokesh Kumar Bhatt
Journal:  Inflammopharmacology       Date:  2021-11-18       Impact factor: 4.473

Review 2.  Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.

Authors:  Shiyao Chen; Yunqi Liu; Huchen Zhou
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 3.  Pro-apoptotic and anti-apoptotic regulation mediated by deubiquitinating enzymes.

Authors:  Hae-Seul Choi; Kwang-Hyun Baek
Journal:  Cell Mol Life Sci       Date:  2022-02-03       Impact factor: 9.261

Review 4.  Deubiquitinases in cancer.

Authors:  Rongbin Wei; Xiaodong Liu; Weixin Yu; Tianshu Yang; Wenping Cai; Junjun Liu; Xiao Huang; Guo-tong Xu; Shouliang Zhao; Jianhua Yang; Shangfeng Liu
Journal:  Oncotarget       Date:  2015-05-30

Review 5.  Inhibition of Ubiquitin-Specific Proteases as a Novel Anticancer Therapeutic Strategy.

Authors:  Tao Yuan; Fangjie Yan; Meidan Ying; Ji Cao; Qiaojun He; Hong Zhu; Bo Yang
Journal:  Front Pharmacol       Date:  2018-09-27       Impact factor: 5.810

6.  Ubiquitination of Rheb governs growth factor-induced mTORC1 activation.

Authors:  Lu Deng; Lei Chen; Linlin Zhao; Yan Xu; Xiaoping Peng; Xinbo Wang; Lin Ding; Jiali Jin; Hongqi Teng; Yanming Wang; Weijuan Pan; Fei Yu; Lujian Liao; Li Li; Xin Ge; Ping Wang
Journal:  Cell Res       Date:  2018-12-04       Impact factor: 25.617

Review 7.  Current Status of SUMOylation Inhibitors.

Authors:  Christopher M Brackett; Brian S J Blagg
Journal:  Curr Med Chem       Date:  2021       Impact factor: 4.530

8.  Ubiquitin-specific peptidase 5, a target molecule of vialinin A, is a key molecule of TNF-α production in RBL-2H3 cells.

Authors:  Yasukiyo Yoshioka; Yue Qi Ye; Kiyoshi Okada; Kayoko Taniguchi; Ayaka Yoshida; Kouichi Sugaya; Jun-ichi Onose; Hiroyuki Koshino; Shunya Takahashi; Arata Yajima; Shunsuke Yajima; Naoki Abe
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

Review 9.  Regulation of Wnt Signaling through Ubiquitination and Deubiquitination in Cancers.

Authors:  Hong-Beom Park; Ju-Won Kim; Kwang-Hyun Baek
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923

Review 10.  Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics.

Authors:  Ainsley Mike Antao; Apoorvi Tyagi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancers (Basel)       Date:  2020-06-15       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.